Incyte (INCY) announced that Dave Gardner has been appointed executive VP and chief strategy officer effective immediately. In his new role, Gardner will serve as a member of the executive leadership team and be responsible for the company’s strategy and business development. Gardner most recently served as partner on the Therapeutics Team at Rock Springs Capital Management.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte price target raised to $115 from $110 at Stifel
- Incyte’s Growth Potential Boosted by Opzelura Approval and Strategic Focus on Myeloproliferative Neoplasms
- Incyte announces additional FDA approval of Opzelura
- Incyte’s Povorcitinib Shows Promise but Faces Competitive Challenges: Hold Rating Maintained
- Incyte announces new data from STOP-HS clinical trial program at EADV